OakChart

Nextcure Inc

NXTCHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

5.980.00 (0.00%)
2026-11-12 02:35 CET
Market cap
27.37 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-40.97 USD m
Free cash flow, TTM
-42.79 USD m
EPS diluted, TTM
-8.66
P/E
-
Compare

Price

NXTC against its 20, 50 and 200-day averages
2050200miss
2.505.007.5010.0055.8M111.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NXTCclose 5.9820-day 5.7850-day 6.04200-day 7.585.9852w low

62.0% under the 52-week high of 15.74 on 24 Nov 2025. 52-week low 1.55 on 26 Jun 2026. Last 15 sessions, 47.1% high to low

Volume 0.91× normal · the line is the 50-bar volume average

Profile

NXTC
52-week range, 31% of the way up
1.5515.74

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Employees40
IPOMay 09, 2019
Beta1.20
ATR, 14d0.83
Rel volume0.91
Short float4.80%
Insider own16.30%
Inst own49.50%

Snapshot

6 groups

Valuation

Index-
Market Cap27.37M
Enterprise Value18.64M
Income-40.97M
Sales0.00M
Book/sh1.20
Cash/sh1.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees40
IPOMay 09, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.97
P/C3.14
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.31
Current Ratio2.31
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-8.66
EPS next Y-1.38
EPS next Q-0.79
EPS this Y67.74%
EPS next Y78.23%
EPS next 5Y60.40%
EPS past 3/5Y15.29% -4.25%
Sales past 3/5Y- -
EPS Y/Y TTM64.21%
Sales Y/Y TTM-
EPS Q/Q59.99%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.-43.33% -

Ownership

Insider Own16.30%
Insider Trans80.30%
Inst Own49.50%
Inst Trans-6.42%
ROA-166.16%
ROE-281.11%
ROIC-744.50%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.46%
SMA50-0.93%
SMA200-21.09%
Trades-

Technical

Shs Outstand4.58M
Shs Float3.83M
Short Float4.80%
Short Ratio1.79
Short Interest0.18M
52W High15.74 -62.01%
52W Low1.55 285.81%
Volatility15.96% 15.25%
ATR (14)0.83
RSI (14)51.33
Beta1.20
Rel Volume0.91
Avg Volume102.56K
Volume93,181

Performance

Perf Week2.22%
Perf Month-4.78%
Perf Quarter-27.78%
Perf Half Y-38.98%
Perf YTD-57.86%
Perf Year-29.81%
Perf 3Y-55.11%
Perf 5Y-92.47%
Perf 10Y-
Recom1.00
Target Price20.00
Prev Close5.98
Price5.98
Change %0.00%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Nov 07, 2025UpgradeLLadenburg ThalmannNeutral → Buy$18+201.0%
Nov 04, 2022DowngradeLLadenburg ThalmannBuy → Neutral
Mar 01, 2022InitiatedLLadenburg ThalmannBuy$16+167.6%
Mar 05, 2021UpgradeTTruistHold → Buy$19+217.7%
Jan 15, 2021DowngradeBBofA SecuritiesNeutral → Underperform$10+67.2%
Jul 16, 2020UpgradeTThe Benchmark CompanyHold → Buy$17+184.3%
Jul 13, 2020DowngradeSSunTrustBuy → Hold
Jul 13, 2020DowngradeRROTH CapitalBuy → Neutral
Jun 01, 2020DowngradeTThe Benchmark CompanyBuy → Hold
Jun 01, 2020DowngradeBBofA/MerrillBuy → Neutral$62 → $40+568.9%

Peers

Mkt cap
TickerCompanyMkt cap
PYXSPyxis Oncology Inc196.16M
KYNBKyntra Bio Inc14.91M
STROSutro Biopharma Inc170.12M
MGNXMacrogenics Inc147.78M
CTMXCytomX Therapeutics Inc464.35M
BOLTBolt Biotherapeutics Inc12.06M
ALXOAlx Oncology Holdings Inc154.87M
ZYMEZymeworks BC Inc2.02B
HOWLWerewolf Therapeutics Inc48.06M
CMPXCompass Therapeutics Inc149.51M

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ADAR1 Capital Management, LLC10% OwnerNov 06 '26Buy5.103,66218,676737,956Nov 09 04:19 PM
ADAR1 Capital Management, LLC10% OwnerNov 05 '26Buy5.101,0245,222734,294Nov 09 04:19 PM
ADAR1 Capital Management, LLC10% OwnerOct 23 '26Buy4.835,62627,170728,045Oct 27 07:36 PM
ADAR1 Capital Management, LLC10% OwnerOct 27 '26Buy5.103,55318,104733,270Oct 27 07:36 PM
ADAR1 Capital Management, LLC10% OwnerOct 26 '26Buy5.031,6728,418729,717Oct 27 07:36 PM
Simcere Zaiming, Inc.Former 10% OwnerAug 10 '26Sale6.1630,000184,800308,636Aug 12 11:35 AM
ADAR1 Capital Management, LLC10% OwnerJul 30 '26Buy4.93292,8501,444,746686,116Aug 03 05:53 PM
ADAR1 Capital Management, LLC10% OwnerJul 31 '26Buy4.9436,303179,375722,419Aug 03 05:53 PM
ADAR1 Capital Management, LLC10% OwnerJul 27 '26Buy5.007,79838,985383,456Jul 29 06:18 PM
ADAR1 Capital Management, LLC10% OwnerJul 28 '26Buy4.956,40031,677389,856Jul 29 06:18 PM
ADAR1 Capital Management, LLC10% OwnerJul 29 '26Buy5.003,41017,050393,266Jul 29 06:18 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 200
  • NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks (Barrons.com)
  • NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire) +6.48%
  • Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders (PR Newswire) +20.75%
  • Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? (PR Newswire) -5.37%
  • Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That (FinanceWire) +201.83%
  • Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
  • NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy (GlobeNewswire)
  • NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers (GlobeNewswire)
  • NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 (GlobeNewswire) -45.48%
  • NextCure Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire) -5.04%
  • NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers (GlobeNewswire)
  • NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 (GlobeNewswire) -6.24%
  • NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-1.290-0.900-1.2890.000.001
2026Q22026-08-06-2.800-1.950-2.8050.000.003
2026Q12026-05-07-1.870-2.105-1.8700.000.002
2025Q42026-03-05-0.460-2.290-2.6920.000.003
2025Q32025-11-05-3.220-3.983-3.2230.000.003
2025Q22025-08-07-11.290-4.615-11.2890.000.002
2025Q12025-05-01-4.680-4.800-4.7030.000.002
2024Q42025-03-06-5.040-4.320-4.9720.000.002
2024Q32024-11-07-4.920-4.140-4.9500.000.002
2024Q22024-08-01-6.600-4.520-6.6080.000.003
2024Q12024-05-02-7.320-5.520-7.3570.000.004
2023Q42024-03-21-6.240-6.503-6.2200.000.004
2023Q32023-11-02-6.120-7.890-6.1640.000.004
2023Q22023-08-03-7.680-6.631-7.7010.000.003
2023Q12023-05-04-6.960-7.438-6.9540.000.003
2022Q42023-03-02-7.440-7.876-7.4740.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-25.800-24.360-25.7946.355.05
2020FY-15.960-16.067-15.95422.3822.34
2021FY-30.120-30.817-30.1520.000.00
2022FY-32.280-31.739-32.3240.000.00
2023FY-27.000-27.307-27.0390.000.00
2024FY-23.880-23.280-23.8820.000.00
2025FY-19.650-17.625-19.6500.000.00
2026FY--6.340--0.00
2027FY--1.380--0.00
2028FY--1.220--6.20
2029FY--0.750--13.60
2030FY-0.120--23.80

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-111000.000.000.00
2026Q4S2026-11-101000.000.000.00
2026Q4S2026-08-131000.000.000.00
2026Q4S2026-08-072000.000.000.00
2026Q4S2026-07-142000.000.000.00
2026Q4S2026-07-131000.000.000.00
2026Q4S2026-05-082000.000.000.00
2026Q4S2026-05-042000.000.000.00
2026Q4S2026-05-021000.000.000.00
2026Q4S2026-03-062000.000.000.00
2026Q4S2025-11-143000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4R2026-11-11100-0.79-0.79-0.79

Estimate history

EPS, annual-8.172-12.045-25.794-15.954-30.152-32.324-27.039-23.882-19.647-8.6554
Period201720182019202020212022202320242025TTM
EPS, quarterly-4.95-4.972-4.703-11.289-3.223-2.692-1.87-2.805-1.289
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual006.34722.378000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.8931.8932.2922.2972.3072.3152.3252.3343.5064.577
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.3312.3342.3342.3382.6763.5063.6084.0694.577
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.0022.386.350.00
Cost of Goods Sold Incl. D&A0.922.192.873.684.484.30--1.68
Gross Profit-0.92-2.19-2.87-3.68-4.48-4.30---1.68
Selling, General and Administrative Excl. Other37.9255.4354.3463.9571.4366.4760.1941.1421.52
Research and Development24.6942.7941.4947.9354.2050.1946.5534.2219.79
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-38.84-57.62-57.21-67.64-75.91-70.77-41.23-37.48-23.20
Interest Expense0.000.000.000.000.000.080.180.210.03
Unusual Expense3.030.002.540.000.000.00---
Net Income Before Taxes-40.97-55.84-55.65-62.72-74.73-69.39-36.60-33.74-22.80
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-40.97-55.84-55.65-62.72-74.73-69.39-36.60-33.74-22.80
Net Income From Continuing Operations-40.97-55.84-55.65-62.72-74.73-69.39-36.60-33.74-22.80
Net Income-40.97-55.84-55.65-62.72-74.73-69.39-36.60-33.74-22.80
EPS (Recurring)-7.32-19.65-23.12-27.04-32.32-30.15-15.95-25.79-12.04
EPS (Basic, Before Extraordinaries)-8.66-19.65-23.88-27.04-32.32-30.15-15.95-25.79-12.04
EPS (Diluted)-8.66-19.65-23.88-27.04-32.32-30.15-15.95-25.79-12.04
EBITDA-37.92-55.43-54.34-63.95-71.43-66.47-37.81-34.79-21.52
Non-Operating Income (Expense)0.911.774.094.911.181.454.803.950.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.282.996.338.199.5110.297.911.890.26
Price To Sales Ratio------13.41139.30-
Operating Margin-------184.22-590.55-
Net Margin-------163.57-531.54-
Shares Outstanding4.583.512.332.332.312.312.302.291.89
Market Capitalization27.3727.3721.5931.7439.13166.09300.501,549.031,209.73

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.270.280.360.530.630.650.67
Gross Profit0.00-0.27-0.28-0.36-0.53-0.63-0.65-0.67
Selling, General and Administrative Excl. Other8.969.749.829.398.4126.6610.9711.78
Research and Development4.547.166.566.445.6224.097.908.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.96-10.02-10.11-9.76-8.95-27.29-11.62-12.46
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-2.045.080.000.000.000.000.000.00
Net Income Before Taxes-6.85-14.89-9.80-9.44-8.62-26.81-10.98-11.60
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.85-14.89-9.80-9.44-8.62-26.81-10.98-11.60
Net Income From Continuing Operations-6.85-14.89-9.80-9.44-8.62-26.81-10.98-11.60
Net Income-6.85-14.89-9.80-9.44-8.62-26.81-10.98-11.60
EPS (Recurring)-1.56-2.14-1.87-2.69-3.22-11.29-4.70-4.97
EPS (Basic, Before Extraordinaries)-1.29-2.80-1.87-2.69-3.22-11.29-4.70-4.97
EPS (Diluted)-1.29-2.80-1.87-2.69-3.22-11.29-4.70-4.97
EBITDA-8.96-9.74-9.82-9.39-8.41-26.66-10.97-11.78
Non-Operating Income (Expense)0.070.200.310.320.320.480.650.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.300.340.430.600.591.361.52
Shares Outstanding4.584.073.613.512.682.342.332.33
Market Capitalization27.375.7838.0349.7415.6812.9013.4521.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments41.8268.62108.30159.91219.63285.15336.31135.639.29
Short Term Receivables0.100.300.800.700.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.832.893.633.378.192.823.680.150.13
Total Current Assets43.7571.81112.72163.98227.82287.98340.00135.789.42
Net Property, Plant & Equipment5.898.7213.4316.9113.9915.8112.0911.4110.02
Total Investments and Advances0.000.000.000.000.001.813.330.000.00
Deferred Tax Assets0.901.061.381.54-----
Other Assets0.550.331.883.270.581.050.750.440.03
Total Assets51.0881.92129.42185.70242.39306.64356.17147.6319.47
Short Term Debt Incl. Current Port. of LT Debt1.000.800.660.520.001.671.670.390.40
Accounts Payable2.015.352.334.271.943.901.860.000.00
Other Current Liabilities7.553.423.904.344.674.7611.519.912.72
Total Current Liabilities10.579.576.889.136.6110.3215.0410.303.12
Long Term Debt4.155.155.956.610.001.813.330.070.46
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.901.061.381.54-----
Other Liabilities0.530.660.790.902.390.7916.3121.980.29
Total Liabilities16.1416.4515.0018.179.0012.9234.6832.353.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00162.2240.00
Common Equity34.9465.47114.42167.53233.39293.72321.48-46.94-24.41
Total Shareholders Equity34.9465.47114.42167.53233.39293.72321.48115.2815.59
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity34.9465.47114.42167.53233.39293.72321.48115.2815.59
Total Liabilities & Stockholders Equity51.0881.92129.42185.70242.39306.64356.17147.6319.47
Book Value Per Share9.9728.0549.2172.38101.18127.85140.29-24.80-12.90
Tangible Book Value Per Share9.9728.0549.2172.38101.18127.85140.29-24.80-12.90
Full-Time Employees404382998790694440
Price to Book Ratio2.000.330.250.220.711.024.827.09-
Return on Assets-83.97-52.67-39.81-34.92-25.28-11.04-13.39-27.29-
Return on Equity-111.23-61.87-44.49-37.28-26.33-11.90-15.45-34.84-
Return on Invested Capital-142.86-78.80-52.11-42.92-29.73-12.39-10.39-19.76-96.39
Quick Ratio4.147.5016.3817.9734.4827.8922.6013.193.02
Current Ratio4.147.5016.3817.9734.4827.8922.6013.193.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-40.97-55.84-55.65-62.72-74.73-69.39-36.60-33.74-22.80
Depreciation0.922.192.873.684.487.203.412.691.68
Other Funds (Non Cash)3.143.097.458.0112.6410.297.911.89-0.15
Funds from Operations-36.91-50.57-45.34-51.03-57.61-51.91-25.28-29.16-21.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.880.954.53-1.943.73-5.34-19.68-6.4628.85
Cash from Operating Activities-42.79-49.61-40.80-52.97-53.89-57.24-44.95-35.627.58
Capital Expenditures0.000.00-0.47-0.82-2.12-2.36-7.13-3.37-3.06
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.700.000.000.000.000.000.000.00-
Purchase or Sale of Investments21.9325.5655.7840.0970.0938.9650.66-300.550.00
Purchase of Investments0.00-26.70-48.45-73.50-34.64-156.48-137.13-300.550.00
Sale Or Maturity of Investments21.9352.26104.23113.60104.74195.44187.780.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities22.6325.5655.3139.2767.9836.6043.52-303.92-3.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock20.3322.310.140.150.200.210.11238.50122.23
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock20.3322.310.140.150.200.210.11238.50122.23
Proceedsfrom Stock Options20.3222.310.120.150.130.000.11238.50122.23
Issuance or Reduction of Debt, Net0.000.000.000.000.00-3.47-1.534.54-0.40
Change in Long Term Debt0.000.000.000.000.00-3.47-1.534.54-0.40
Issuance of Long Term Debt0.000.000.000.000.000.000.004.540.00
Reduction of Long Term Debt0.000.000.000.000.00-3.47-1.530.00-0.40
Net Financing Active Other Cash Flow1.230.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities21.5622.310.140.150.20-3.27-1.42243.04121.83
Net Change in Cash1.40-1.7514.64-13.5514.29-23.91-2.85-96.50126.35
Free Cash Flow-42.79-49.61-41.28-53.79-56.00-59.60-52.09-38.994.52
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments8.7320.0929.7441.8229.1135.31
Short Term Receivables0.000.100.100.100.300.20
Inventories0.000.000.000.000.000.00
Other Current Assets0.972.071.901.833.234.51
Total Current Assets9.7022.2531.7443.7532.6440.02
Net Property, Plant & Equipment0.000.285.395.896.427.12
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.00-----
Deferred Tax Assets---0.90--
Other Assets0.000.080.850.550.550.56
Total Assets9.7022.6237.9851.0839.6147.69
Short Term Debt Incl. Current Port. of LT Debt0.000.681.051.000.330.64
Accounts Payable2.962.583.072.012.392.54
Other Current Liabilities1.243.152.777.558.277.60
Total Current Liabilities4.206.416.8910.5710.9910.78
Long Term Debt0.003.603.884.154.414.67
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.90--
Other Liabilities0.000.460.490.530.560.60
Total Liabilities4.2010.4711.2616.1415.9716.04
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.5012.1526.7234.9423.6531.65
Total Shareholders Equity5.5012.1526.7234.9423.6531.65
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.5012.1526.7234.9423.6531.65
Total Liabilities & Stockholders Equity9.7022.6237.9851.0839.6147.69
Book Value Per Share1.202.997.419.978.8413.54
Tangible Book Value Per Share1.202.997.419.978.8413.54
Full-Time Employees---40--
Price to Book Ratio2.000.221.071.610.430.41
Return on Assets-166.16-121.60-104.01-83.97-89.28-81.09
Return on Equity-281.11-195.22-132.40-111.23-116.91-104.07
Return on Invested Capital-124.40-94.54-32.02-24.14-30.74-73.83
Quick Ratio2.313.474.614.142.973.71
Current Ratio2.313.474.614.142.973.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.85-14.89-9.80-9.44-8.62-26.81
Depreciation0.000.270.280.360.530.63
Other Funds (Non Cash)-3.345.500.440.540.700.58
Funds from Operations-10.19-9.12-9.07-8.53-7.39-25.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.89-0.60-4.290.901.122.88
Cash from Operating Activities-12.07-9.71-13.36-7.64-6.27-22.71
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.700.000.000.000.000.00
Purchase or Sale of Investments4.849.791.306.008.703.76
Purchase of Investments0.000.000.000.000.00-12.74
Sale Or Maturity of Investments4.849.791.306.008.7016.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.549.791.306.008.703.76
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.020.0120.290.002.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.020.0120.290.002.02
Proceedsfrom Stock Options0.000.020.0020.290.002.02
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.001.230.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.021.2520.290.002.02
Net Change in Cash-6.530.09-10.8118.662.43-16.93
Free Cash Flow-12.07-9.71-13.36-7.64-6.27-22.71

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.80%0.2M3.8M150.95K
2026-10-155.77%0.2M3.8M297.11K
2026-09-305.57%0.2M3.8M2.11M
2026-09-152.75%0.1M3.8M2.15M
2026-08-311.20%0.0M3.8M2.14M
2026-08-144.49%0.1M3.3M2.16M
2026-07-315.19%0.1M2.7M2.10M
2026-07-1549.58%1.3M2.7M1.97M
2026-06-306.69%0.2M2.4M96.96K
2026-06-159.32%0.2M2.4M80.62K
2026-05-292.84%0.1M2.4M50.31K
2026-05-152.40%0.1M2.4M47.73K
2026-04-302.99%0.1M2.4M49.68K
2026-04-153.03%0.1M2.4M40.21K
2026-03-313.47%0.1M1.6M35.19K
2026-03-133.53%0.1M1.6M34.40K
2026-02-273.50%0.1M1.6M34.97K
2026-02-133.93%0.1M1.6M40.23K
2026-01-303.03%0.0M1.6M40.61K
2026-01-152.55%0.0M1.9M60.84K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-06EFFECTEffectiveness filing by commission orderSEC
2026-11-06424B3SEC
2026-11-06S-4/ASEC
2026-11-02S-4/ASEC
2026-10-308-KCurrent report2026-10-26SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-20SCHEDULE 13GSEC
2026-10-01S-4/ASEC
2026-09-25425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-258-KCurrent report2026-09-21SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-08-18S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-12SCHEDULE 13GSEC
2026-08-10425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-04425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-293Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-16425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-14425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1123.90K200
2026-1053.69K300
2026-090000
2026-0800184.80K1
2026-071.71M500
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Ikarian Capital, LLC7.98%
ADAGE CAPITAL PARTNERS GP, L.L.C.7.67%
Sofinnova Investments, Inc.6.16%
RENAISSANCE TECHNOLOGIES LLC4.74%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
MILLENNIUM MANAGEMENT LLC2.44%
BOOTHBAY FUND MANAGEMENT, LLC2.34%
Squadron Capital Management LLC1.78%
GEODE CAPITAL MANAGEMENT, LLC1.71%
Verdad Advisers, LP1.67%

Funds

Fund% owned
Select Health Care Portfolio29.81%
Select Biotechnology Portfolio23.20%
Fidelity Small Cap Growth Fund19.38%
Fidelity Small Cap Growth K6 Fund10.06%
Fidelity Advisor Health Care Fund6.84%
Fidelity Advisor Biotechnology Fund4.80%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.41%
Fidelity Nasdaq Composite Index Fund1.09%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
Fidelity Extended Market Index Fund0.43%

OakChart. NXTC. Cached 15 minutes.